Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 20:04 ET | Source: DiCello Levitt LLP

SHAREHOLDER ALERT: DiCello Levitt LLP Announces That A Shareholder Class Action Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)

DiCello Levitt LLP: MoonLake investors wishing to serve as lead plaintiff have until December 15, 2025, to petition the Court.
October 15, 2025 11:18 ET | Source: Block & Leviton LLP

SHAREHOLDER ALERT: MoonLake Immunotherapeutics Sued For Securities Fraud by Block & Leviton LLP; December 15 Deadline To Seek To Serve As Lead Plaintiff

Block & Leviton filed a class action lawsuit today against MoonLake Immunotherapeutics (Nasdaq: MLTX). Investors should contact the firm by December 15.
February 13, 2025 11:55 ET | Source: Spherix Global Insights

Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market

EXTON, PA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis (PsA) market, with early indicators suggesting it could drive a...
January 22, 2024 10:47 ET | Source: Spherix Global Insights

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld their...